Company intelligence / Profile preview

Agalimmune Ltd

Ownership: Private
Development stage: Phase 3

Overview

In a Phase 1/2a trial, AGI-134 demonstrated a favorable safety profile and initiated immune activity in patients. 29% of patients achieved stable disease, with 7 of 11 patients who achieved stable disease having previously failed checkpoint-inhibitor therapy[6].

Therapeutic areas: Oncology
Modalities: ImmunotherapyCancer vaccine
Industry: Biotech

Drug pipeline

3 assets

motixafortide

Phase 3

Indications: Multiple myeloma, Pancreatic cancer, Acute myeloid leukemia

2 more assets in the full pipeline.

Request access →

Partnerships

University of Massachusetts Medical SchoolKODE Biotech[4][5]

Beyond the preview

Go deeper on Agalimmune Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agalimmune Ltd.

Explore the full profile